Our AI-based approach is designed to:
- Enhance R&D efficiencies
- Shorten development timelines
- Increase probability of success
Sep 19, 2024
BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationVIEW RELEASE
Sep 05, 2024
BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Aug 07, 2024
BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth ConferenceVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Oct 07, 2024 03:53 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
0.5492
CHANGE
-0.0356 (-6.09%)